Pharmaceutical

Regeneron to acquire rights for Hansoh’s HS-20094 therapy

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS-20094.

Jun 3, 2025 - 06:00
Regeneron to acquire rights for Hansoh’s HS-20094 therapy
Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS-20094.
Read the original article

Tags:

Previous Article

Biosensors Revolutionize Gastrointestinal Tumor Detection

Next Article

ASCO25: Amgen’s Nplate proves effective in GI cancer-linked thrombocytopaenia

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: In ‘march-in’ rights, some see a tool to lower drug prices. Others see a threat to intellectual property

STAT+: In ‘march-in’ rights, some see a tool to lower d...

Jan 22, 2024

UK life science startups have trouble “scaling up” says Lord Vallance

UK life science startups have trouble “scaling up” says...

Nov 21, 2024

Roche announces $50bn US investment in pharma and diagnostics

Roche announces $50bn US investment in pharma and diagn...

Apr 22, 2025